JP2013542264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542264A5 JP2013542264A5 JP2013538939A JP2013538939A JP2013542264A5 JP 2013542264 A5 JP2013542264 A5 JP 2013542264A5 JP 2013538939 A JP2013538939 A JP 2013538939A JP 2013538939 A JP2013538939 A JP 2013538939A JP 2013542264 A5 JP2013542264 A5 JP 2013542264A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- inhibition
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- 230000005764 inhibitory process Effects 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 6
- 229960000397 bevacizumab Drugs 0.000 claims 6
- 229960004562 carboplatin Drugs 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 230000000970 DNA cross-linking effect Effects 0.000 claims 2
- 230000002112 DNA intercalation Effects 0.000 claims 2
- 230000006820 DNA synthesis Effects 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 101710183280 Topoisomerase Proteins 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- -1 bevacizumab Chemical compound 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 0 CC(C)=CCCNc(cc1)ccc1C(NC(CCC(NCC(NC(CCCNC(N)=N)C(NCC(N[C@@](CC(O)=O)C(NC(*)CSSCCOC(NNC([C@]1(C(*)C2C=CCN(CC3)C2C32c(cc(C)c(OC)c3)c3N(C)C12)O)=O)=O)=O)=O)=O)=O)=O)C=O)=O Chemical compound CC(C)=CCCNc(cc1)ccc1C(NC(CCC(NCC(NC(CCCNC(N)=N)C(NCC(N[C@@](CC(O)=O)C(NC(*)CSSCCOC(NNC([C@]1(C(*)C2C=CCN(CC3)C2C32c(cc(C)c(OC)c3)c3N(C)C12)O)=O)=O)=O)=O)=O)=O)=O)C=O)=O 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VORHXBNOSKWXDL-UHFFFAOYSA-N NC(C(N)=O)=C(N)N Chemical compound NC(C(N)=O)=C(N)N VORHXBNOSKWXDL-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41327510P | 2010-11-12 | 2010-11-12 | |
| US61/413,275 | 2010-11-12 | ||
| PCT/US2011/060407 WO2012065085A1 (en) | 2010-11-12 | 2011-11-11 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013542264A JP2013542264A (ja) | 2013-11-21 |
| JP2013542264A5 true JP2013542264A5 (https=) | 2014-12-25 |
Family
ID=46048353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538937A Pending JP2013542263A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
| JP2013538939A Pending JP2013542264A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538937A Pending JP2013542263A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8987281B2 (https=) |
| EP (2) | EP2638395A4 (https=) |
| JP (2) | JP2013542263A (https=) |
| KR (2) | KR20130140032A (https=) |
| CN (2) | CN103282777A (https=) |
| AU (2) | AU2011325989C1 (https=) |
| BR (2) | BR112013011590A2 (https=) |
| CA (2) | CA2817223A1 (https=) |
| CL (2) | CL2013001324A1 (https=) |
| EA (2) | EA026168B1 (https=) |
| IL (2) | IL226247A0 (https=) |
| MX (2) | MX2013005196A (https=) |
| SG (2) | SG190244A1 (https=) |
| WO (2) | WO2012065085A1 (https=) |
| ZA (2) | ZA201304226B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| KR20130140032A (ko) | 2010-11-12 | 2013-12-23 | 엔도사이트, 인코포레이티드 | 암을 치료하는 방법들 |
| SG194458A1 (en) * | 2011-04-12 | 2013-12-30 | Endocyte Inc | Solid pharmaceutical composition |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| WO2015077303A1 (en) | 2013-11-19 | 2015-05-28 | Purdue Research Foundation | Patient selection method for inflammation |
| KR102410090B1 (ko) | 2014-02-21 | 2022-06-16 | 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 | 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 |
| CN103816548A (zh) * | 2014-03-11 | 2014-05-28 | 北京林业大学 | 靶向亲水性聚合物-雷公藤甲素结合物 |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2015160833A1 (en) * | 2014-04-14 | 2015-10-22 | Endocyte, Inc. | Drug delivery conjugates for treating resistant cancer and for use in combination therapy |
| CN112638363B (zh) * | 2018-08-31 | 2025-01-24 | 太阳医药工业有限公司 | 卡铂的肠胃外剂型 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| CA2484640C (en) * | 2002-05-15 | 2012-01-17 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| WO2004069159A2 (en) * | 2003-01-27 | 2004-08-19 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
| ATE460668T1 (de) * | 2005-03-30 | 2010-03-15 | Purdue Research Foundation | Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren |
| EP2382995A3 (en) * | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
| US20070065449A1 (en) | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| ES3029483T3 (en) * | 2008-09-17 | 2025-06-24 | Endocyte Inc | Folate receptor binding conjugates of antifolates |
| WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
| BR112012002064A2 (pt) | 2009-07-31 | 2017-05-09 | Endocyte Inc | método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele |
| KR20130140032A (ko) | 2010-11-12 | 2013-12-23 | 엔도사이트, 인코포레이티드 | 암을 치료하는 방법들 |
-
2011
- 2011-11-11 KR KR1020137013270A patent/KR20130140032A/ko not_active Ceased
- 2011-11-11 KR KR1020137013272A patent/KR20130140033A/ko not_active Ceased
- 2011-11-11 BR BR112013011590-4A patent/BR112013011590A2/pt not_active IP Right Cessation
- 2011-11-11 US US13/294,624 patent/US8987281B2/en not_active Expired - Fee Related
- 2011-11-11 CA CA2817223A patent/CA2817223A1/en not_active Abandoned
- 2011-11-11 CN CN2011800634321A patent/CN103282777A/zh active Pending
- 2011-11-11 AU AU2011325989A patent/AU2011325989C1/en not_active Ceased
- 2011-11-11 EA EA201390695A patent/EA026168B1/ru not_active IP Right Cessation
- 2011-11-11 JP JP2013538937A patent/JP2013542263A/ja active Pending
- 2011-11-11 EP EP11839397.4A patent/EP2638395A4/en not_active Withdrawn
- 2011-11-11 WO PCT/US2011/060407 patent/WO2012065085A1/en not_active Ceased
- 2011-11-11 AU AU2011325982A patent/AU2011325982C1/en not_active Ceased
- 2011-11-11 JP JP2013538939A patent/JP2013542264A/ja active Pending
- 2011-11-11 SG SG2013036280A patent/SG190244A1/en unknown
- 2011-11-11 EP EP11840607.3A patent/EP2638397A4/en not_active Withdrawn
- 2011-11-11 EA EA201390694A patent/EA025069B1/ru not_active IP Right Cessation
- 2011-11-11 WO PCT/US2011/060395 patent/WO2012065079A1/en not_active Ceased
- 2011-11-11 SG SG2013036306A patent/SG190245A1/en unknown
- 2011-11-11 BR BR112013011659A patent/BR112013011659A2/pt not_active IP Right Cessation
- 2011-11-11 US US13/884,842 patent/US8883737B2/en not_active Expired - Fee Related
- 2011-11-11 MX MX2013005196A patent/MX2013005196A/es unknown
- 2011-11-11 CN CN201180061415.4A patent/CN103403552B/zh not_active Expired - Fee Related
- 2011-11-11 CA CA2817219A patent/CA2817219A1/en not_active Abandoned
- 2011-11-11 MX MX2013005194A patent/MX2013005194A/es unknown
-
2013
- 2013-03-13 US US13/800,254 patent/US20140066383A1/en not_active Abandoned
- 2013-05-09 IL IL226247A patent/IL226247A0/en unknown
- 2013-05-09 IL IL226246A patent/IL226246A0/en unknown
- 2013-05-13 CL CL2013001324A patent/CL2013001324A1/es unknown
- 2013-05-13 CL CL2013001322A patent/CL2013001322A1/es unknown
- 2013-06-10 ZA ZA2013/04226A patent/ZA201304226B/en unknown
- 2013-06-10 ZA ZA2013/04225A patent/ZA201304225B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542264A5 (https=) | ||
| JP2013542263A5 (https=) | ||
| JP2014525449A5 (https=) | ||
| CN103945902B (zh) | 地西他滨衍生物制剂 | |
| RU2723590C2 (ru) | Лиофилизированные фармацевтические композиции | |
| WO2007082978A1 (es) | Una formulación farmacéutica de taxano, una composición sólida de taxano, un procedimiento para la preparación de dicha composición sólida de taxano, una composición solubilizante de dicha composición sólida de taxano, y un conjunto de elementos (kit) par | |
| ES2414472T3 (es) | Composición farmacéutica de liberación sostenida de acetato de octreotide | |
| JP2019526596A5 (https=) | ||
| JP2017511360A5 (https=) | ||
| RU2016141569A (ru) | Комбинации | |
| JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
| KR20170023088A (ko) | 정제된 치료용 나노입자 및 이의 제조방법 | |
| JP2019515908A5 (https=) | ||
| JP2015535243A5 (https=) | ||
| JP2011507838A5 (https=) | ||
| CN111888329A (zh) | 注射剂 | |
| CN107405404A (zh) | 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途 | |
| WO2014165829A3 (en) | Nanoparticle formulations | |
| Li et al. | Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer | |
| EP1965804A2 (en) | Lyophilized compositions of a triazolopyrimidine compound | |
| RU2018114922A (ru) | Лечение очаговой алопеции | |
| WO2016008401A1 (zh) | 一种含多西他赛的药物组合物 | |
| JP4891912B2 (ja) | 非水性極性溶媒中の１０−ヒドロキシカンプトテシン化合物の溶解度を増加させるための薬剤製剤 | |
| JP2015526504A5 (https=) | ||
| WO2012029076A2 (en) | Stable pharmaceutical composition |